Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar:224:108665.
doi: 10.1016/j.clim.2021.108665. Epub 2021 Jan 8.

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases"

Rossella Talotta  1
Affiliations
Comment

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases"

Rossella Talotta. Clin Immunol. 2021 Mar.
No abstract available

Keywords: Autoimmunity; Autoinflammation; COVID-19; Immune response; SARS-CoV-2; Type I interferon; mRNA vaccine.

PubMed Disclaimer

Conflict of interest statement

The author has no competing interests to declare.

Comment in

  • Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19.
    Bautista García J, Peña Ortega P, Bonilla Fernández JA, Cárdenes León A, Ramírez Burgos L, Caballero Dorta E. Bautista García J, et al. Rev Esp Cardiol (Engl Ed). 2021 Sep;74(9):812-814. doi: 10.1016/j.rec.2021.04.005. Epub 2021 Apr 27. Rev Esp Cardiol (Engl Ed). 2021. PMID: 33994339 Free PMC article. No abstract available.

Comment on

References

    1. Vojdani A., Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. 2020;217 doi: 10.1016/j.clim.2020.108480. - DOI - PMC - PubMed
    1. Talotta R., Robertson E. Autoimmunity as the comet tail of COVID-19 pandemic. World J. Clin. Cases. 2020;8:3621–3644. doi: 10.12998/wjcc.v8.i17.3621. - DOI - PMC - PubMed
    1. Goriely S., Goldman M. From tolerance to autoimmunity: is there a risk in early life vaccination? J. Comp. Pathol. 2007;137:S57–S61. doi: 10.1016/j.jcpa.2007.04.013. - DOI - PubMed
    1. Kostoff R.N., Kanduc D., Porter A.L., Shoenfeld Y., Calina D., Briggs M.B., Spandidos D.A., Tsatsakis A. Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety. Toxicol. Reports. 2020;7:51–64. doi: 10.1016/j.toxrep.2020.10.016. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck R.W., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U., Gruber W.C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed